Collin Blakely, MD, PhD

Trials

Studies that name Collin Blakely, MD, PhD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 12:40 UTC. Open this list on ClinicalTrials.gov

• Ph1
  NCT04085315 · Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer

  Collin Blakely · completed · Lung Cancer Metastatic, EGFR Gene Mutation · principal investigator
• Ph1
  NCT04005144 · Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer

  University of California, San Francisco · terminated · ALK Gene Rearrangement, Lung Non-Small Cell Carcinoma, Progressive Disease · principal investigator
• Ph2
  NCT03433469 · Osimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before Surgery

  University of California, San Francisco · active not recruiting · Stage I Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Cancer, Stage IB Non-Small Cell Lung Cancer · principal investigator
• Ph2
  NCT03232892 · Trametinib in Patients With Advanced Neurofibromatosis Type 1 (NF1)-Mutant Non-small Cell Lung Cancer

  University of California, San Francisco · terminated · Non-small Cell Lung Cancer · study chair
• Ph1
  NCT03087448 · Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

  University of California, San Francisco · terminated · Non-small Cell Lung Cancer · principal investigator

Grants

NIH projects from RePORTER, fetched 2026-11-12 12:40 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.

No NIH project could be tied to this name by a shared trial or a matching institution.